2. About Us…

4. LOCATIONDOSAGE FORMAPPROVALS GOA I TABLETS, CREAMS & OINTMENTS US-FDA EU-GMP TGA Australia MCC South Africa ANVISA – Brazil GOA II STERILE PRODUCTS Same as above GOA III TABLETS US-FDA EU-GMP TGA Australia WALUJ TABLETS Emerging Markets BADDI TABLETS, LIQUID ORALS & TOOTHPASTES EU–GMP and Emerging Markets PATALGANG A APIs US-FDA, TGA Australia KILOLAB APIs US-FDA, TGA Australia Regulatory Approvals

5. Branded Generics Active Pharmaceutical Ingredients (APIs) (Captive Consumption & Supply to end users) Regulated Markets - Generics - CRAMS Emerging Markets - Branded Generics AnaCipher - CRO for BA / BE Studies - Analytical Services Xtend Industrial Designers and Engineers Business Model

6. TOP BRANDS CYCLOPAM FEBREX PLUS SENSODENT K ATM OXIPOD CITAL SENSOFORM CLOBEN G SENSODENT KF KARVOL PLUS Marketing DivisionsMain Doctor Specialties INDOCOMulti Specialty Division SPADEGP, CP, ENT, Pediatrician Warren ACEDentists Warren NXGenDentists / Super specialties within Dentistry SPERAGynecologists, General Practitioners FOCUSConsulting Physicians INDOCO CND Cardiologists, Diabetologists, Consulting Physicians EXCELOphthalmologists ETERNAOrthopedicians IMPULSE / INSTITUTIONPrivate Corporate Hospitals & Govt. Institutions Indian Formulation Business Indoco generates around 50 Million Prescriptions Annually (Source : CMARC)

7. Increasing income levels, rapid urbanization, changing lifestyle, rapid expansion in healthcare insurance sector, demand for quality healthcare services Brand building and focus on chronic segment Penetration in Northern and Eastern Regions to achieve regional balance New Products introductions (Around 20 products including brand extensions every year) Focus on developing sustainable Rx support from core prescribers of Indoco brands Significant API contribution with expanded product basket and services Indian Business - Growth Drivers

8. Revenue of ` 252 Crs in 2014-15 Revenue contribution (Europe 46%, USA 24 %, SA & ANZ 17%) CRAMS, FDF, APIs MAs / Dossier Out-Licensing Regulated Markets (87% of Exports) Revenue of ` 39 Crs in 2014-15 Revenue Contribution (Africa 9%, Asia 2%, Latam 2% ) Promotion of Branded Generics through Distributors Emerging Markets (13% of Exports) International Business

9. International Business - Growth Drivers Partnership and alliances to provide impetus to international business Regulatory approvals from countries including US / Europe for manufacturing facilities and products Own filing of ANDAs and Dossiers Shift from CRAMS to supplies against own dossiers / marketing authorizations in regulated markets Creation of own Intellectual Property through Patents and Trademarks NDDS and new platform technologies for future commercial exploitation

10. Financials Particulars Quarter EndedYTD Year Ended 30.09.1530.09.14 Gwth %30.09.1530.09.14 Gwth %31.03.1531.03.14Gwth % Net Revenues 24767226429.446364424379.3848907173718.3 PAT 226222410.9428942451.08281579043.0 % to Sales 9.19.9 9.310.09.88.1 EBIDTA 45754863(5.9)883585203.7165191200737.6 % to Sales 18.521.5 19.120.119.516.7 Operating Profit 37173769(1.4)691266354.212941847952.6 % to Sales 15.016.6 14.915.615.211.8 Earnings per Share (EPS) Face Value (` 2/-) 2.452.43 4.654.618.996.28 (` in Lacs)

11. Share Holding Pattern and MCAP 523 Mar'13 1217 Mar'14 3352 Mar'15 Increase in Shareholder’s Wealth (` in Crs)

12. Strategies – - Run healthy core businesses - Leverage strengths into new products and services - Open new frontiers, viz., CRO, Allied Services Core Competencies – - Detailed customer knowledge and focus - Large scale systems integration - Lean enterprise - To embark upon proactive measures (e.g. GST, SAP, IFRS,etc) Values – - Integrity - Quality - Customer satisfaction - Team spirit - Good corporate citizenship - Leadership Roadmap for Growth

13. Thank You